Skip to content

Quick ratio at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
4.1×-5.5×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
1.9×-0.4×
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
2.5×+0.5×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
7.6×-0.7×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
1.5×-3.1×
PVL
Palvella TherapeuticsPVLA
28.9×+20.0×

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%

Returns & leverage

See full
Return on equity-882.8%
Debt / equity0.1×
Current ratio1.9×-1.0×

Where this comes from

Calculated from BioCryst Pharmaceuticals’s reported figures.

Based on the most recent quarter.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's quick ratio?
BioCryst Pharmaceuticals (BCRX) reported quick ratio of 1.8× in Q1 2026.
How has BioCryst Pharmaceuticals's quick ratio changed year-over-year?
BioCryst Pharmaceuticals's quick ratio decreased by 35.8% year-over-year, from 2.8× to 1.8×.
What is the long-term trend for BioCryst Pharmaceuticals's quick ratio?
Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's quick ratio has grown at a -8.3% compound annual growth rate (CAGR), from 3× to 1.9×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.